Abstract
Pulmonary Circulation, April-June, 2012; Vol 2; Issue 2 Title: Clinical perspectives with long-term pulsed inhaled nitric oxide for the treatment of pulmonary arterial hypertension The sentences pertaining should be read as follows “Conflict of Interest: None declared” Should read as “Conflict of Interest: Dr. Barst has been a member of the speakers' bureau for Actelion Pharmaceuticals US, Inc. and Gilead; has been a consultant and has received honoraria for speaking engagements as an invited speaker for Actelion Pharmaceuticals US, Inc.; Bayer HealthCare Pharmaceuticals; Eli Lilly and Company; Gilead; Ikaria, Inc.; Merck & Co., Inc.; Novartis Pharmaceuticals Corporation; Pfizer Inc; and VentriPoint, Inc.; and is a shareholder of VentriPoint, Inc. stock. Dr. Channick has received grant/research support from and has been a consultant for Ikaria, Inc. and Actelion Pharmaceuticals US, Inc. He has participated in formal advisory activities for Ikaria, Inc.; Actelion Pharmaceuticals US, Inc.; and United Therapeutics Corporation. The University of Colorado receives fees for Dr. Ivy to be a consultant for Actelion Pharmaceuticals US, Inc.; Gilead; Pfizer Inc; and United Therapeutics Corporation. Dr. Goldstein is an employee of Ikaria, Inc.” The error is regretted —Chief Editor, PC
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.